accountmany conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Amira Pharmaceuticals To Present Preclinical Data On AM152 , An LPA1 Receptor Antagonist, At The Annual Meeting Of The American Thoracic Society
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account